Greenwich LifeSciences, Inc. (NASDAQ:GLSI) VP Jaye Thompson Purchases 1,000 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson bought 1,000 shares of the company's stock in a transaction that occurred on Thursday, November 21st. The stock was purchased at an average price of $12.91 per share, with a total value of $12,910.00. Following the transaction, the vice president now directly owns 264,148 shares in the company, valued at $3,410,150.68. The trade was a 0.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Greenwich LifeSciences Stock Performance

Shares of Greenwich LifeSciences stock traded up $0.39 during midday trading on Monday, reaching $13.94. 29,419 shares of the company's stock traded hands, compared to its average volume of 39,686. The company has a market cap of $183.31 million, a PE ratio of -17.42 and a beta of 1.62. The stock has a 50 day moving average of $13.80 and a 200-day moving average of $14.43. Greenwich LifeSciences, Inc. has a 12 month low of $8.00 and a 12 month high of $21.44.

Hedge Funds Weigh In On Greenwich LifeSciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company's stock worth $4,449,000 after acquiring an additional 1,420 shares during the last quarter. State Street Corp boosted its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company's stock valued at $1,026,000 after buying an additional 3,005 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after buying an additional 5,861 shares during the last quarter. Barclays PLC boosted its position in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company's stock valued at $123,000 after buying an additional 6,538 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in Greenwich LifeSciences in the second quarter valued at about $117,000. Institutional investors own 4.16% of the company's stock.

Analyst Ratings Changes

Separately, HC Wainwright boosted their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a "buy" rating in a research report on Friday, August 23rd.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.